Cervical Spondylotic Myelopathy Clinical Trials 2023

What are the top hospitals conducting cervical spondylotic myelopathy research?

When it comes to cutting-edge clinical trials for cervical spondylotic myelopathy, several hospitals are leading the way in different parts of the United States. In Philadelphia, Thomas Jefferson University is making strides with three active trials focused on this condition, marking their dedication to finding innovative solutions since their first recorded trial in 2012. The Kessler Foundation in West Orange also stands out with two ongoing trials and a recent entry into this field in 2021.

Meanwhile, the Spine Institute of Louisiana is actively conducting two clinical trials for cervical spondylotic myelopathy but does not have any previous completed studies available at this time. This highlights their commitment to exploring new treatments and interventions for patients dealing with this disorder.

In New york City, the Hospital for Special Surgery has been dedicated to advancing knowledge about cervical spondylotic myelopathy since recording its first trial in 2014. Currently engaged in two active trials themselves, they serve as an important hub for research and innovation in this field.

Last but not least is the Texas Back Institute located in Plano - another significant contributor to cervical spondylotic myelopathy research. With two ongoing clinical trials and one previously conducted trial recorded back in 2018, they continue to push boundaries and explore potential breakthroughs that could improve patient outcomes and quality of life.

These hospitals represent beacons of hope within the medical community as they work tirelessly towards better understanding cervical spondylotic myelopathy while developing novel treatment approaches. Through collaboration and scientific advancements across different locations throughout the country, we can look forward to enhanced care options that will benefit individuals affected by this condition.

Which are the best cities for cervical spondylotic myelopathy clinical trials?

When it comes to clinical trials for cervical spondylotic myelopathy, several cities have emerged as leaders in research and development. New york, with 6 active trials, focuses on studying treatments like prodisc C SK and/or Vivo, Dorsal, among others. Philadelphia follows closely behind with 4 ongoing studies investigating various treatment approaches including experimental options and the Posterior Cervical Stabilization System (PCSS). Salt Lake City also plays a significant role with 3 active trials exploring interventions such as Fitbit and different surgical techniques like prodisc C SK and/or Vivo, Dorsal. Although Minneapolis and West Orange have fewer active trials in this area of study (2 each), they still contribute valuable insights into areas such as ergonomic wheelchair gear testing. These cities collectively offer patients access to cutting-edge clinical trials that provide hope for advancements in the management of cervical spondylotic myelopathy.

Which are the top treatments for cervical spondylotic myelopathy being explored in clinical trials?

Clinical trials exploring treatments for cervical spondylotic myelopathy have identified two promising contenders. Remote CMR and Definity Perflutren Lipid Microsphere Ultrasound Contrast are currently being investigated in one active trial each, exclusively focused on this condition. Both therapies were first listed in 2023, suggesting recent advancements in the search for effective interventions. As researchers delve deeper into these treatment options, they hold the potential to bring relief to individuals suffering from cervical spondylotic myelopathy.

What are the most recent clinical trials for cervical spondylotic myelopathy?

Exciting advancements are occurring in the field of cervical spondylotic myelopathy (CSM) with recent clinical trials offering potential new treatments. One such trial is investigating the use of istradefylline, which has reached Phase 1 and Phase 2 stages, demonstrating promising results for CSM patients. Another trial explores remote CMR as a diagnostic tool for CSM, providing an innovative approach to assessing spinal cord function remotely. Additionally, teriflunomide displays promise as a therapeutic option for CSM through its ongoing Phase 1 and Phase 2 studies. Locomotor training also shows potential benefits in improving mobility for individuals affected by CSM during its current Phase 2 investigation. While these trials hold great promise, it's important to note that further research is needed before any definitive conclusions can be drawn regarding their effectiveness in managing this condition effectively.

What cervical spondylotic myelopathy clinical trials were recently completed?

Recently completed clinical trials focused on cervical spondylotic myelopathy have made significant progress in advancing treatment options for this condition. Notably, the Washington University School of Medicine successfully concluded a trial investigating a potential therapy called Uproleselan in October 2021. Another notable development was the completion of a trial for an experimental treatment known as mRNA-1273 sponsored by the National Cancer Institute (NCI) in September 2021. These recent achievements highlight the dedication and efforts of researchers to find effective interventions for patients with cervical spondylotic myelopathy.